UNIVERSITY OF CALIFORNIA, DAVIS

🇺🇸United States

Country: 🇺🇸United States

Ownership: Private, Subsidiary

Established: 1905-01-01

Employees: 10K

Market Cap: -

Website: http://www.ucdavis.edu

Clinical Trials

Effects of L-arginine Supplementation in Adults With Moderate to Severe Asthma

Phase 2

Completed

Conditions: Asthma

Interventions: Drug: Placebo
Drug: L-arginine

First Posted Date: 2006-01-23

Last Posted Date: 2017-05-30

Lead Sponsor: University of California, Davis

Target Recruit Count: 20

Registration Number: NCT00280683

Locations: 🇺🇸
University of California, Davis General Clinical Research Center, Sacramento, California, United States

Brief Intervention for Alcohol Use Among Injured Patients

Not Applicable

Active, not recruiting

Conditions: Wounds and Injuries
Alcohol Drinking

Interventions: Behavioral: Brief Motivational Interview

First Posted Date: 2006-01-18

Last Posted Date: 2024-01-02

Lead Sponsor: University of California, Davis

Target Recruit Count: 830

Registration Number: NCT00278785

Locations: 🇺🇸
University of California, Davis, Medical Center, Sacramento, California, United States

Study of Using Computerized Education to Increase Patients' Confidence in Their Ability to Be Screened for Colon Cancer

Phase 3

Completed

Conditions: Colorectal Cancer Screening

First Posted Date: 2006-01-09

Last Posted Date: 2006-09-08

Lead Sponsor: University of California, Davis

Target Recruit Count: 100

Registration Number: NCT00273585

Locations: 🇺🇸
Department of Family & Community Medicine, UC Davis School of Medicine, Sacramento, California, United States

Effects of GCP on Prostate Cancer.

Not Applicable

Completed

Conditions: Prostate Cancer

First Posted Date: 2005-12-23

Last Posted Date: 2010-06-29

Lead Sponsor: University of California, Davis

Target Recruit Count: 62

Registration Number: NCT00269555

Locations: 🇺🇸
University of California, Davis, Sacramento, California, United States

Postoperative Telerounding: A Multi-Center Prospective Randomized Assessment of Patient Outcomes and Satisfaction.

Completed

Conditions: Kidney Cancer
Ureteral Cancer
Prostate Cancer
Nephrolithiasis

First Posted Date: 2005-12-07

Last Posted Date: 2006-05-31

Lead Sponsor: University of California, Davis

Target Recruit Count: 270

Registration Number: NCT00263107

Locations: 🇺🇸
University of California, Davis, Sacramento, California, United States
🇺🇸
Centerra Health, Norfolk, Virginia, United States
🇺🇸
Johns Hopkins, Baltimore, Maryland, United States

Use of Robotic Telerounding After Operative Procedures

Not Applicable

Completed

Conditions: Post-Operative in-Patients

First Posted Date: 2005-12-02

Last Posted Date: 2005-12-02

Lead Sponsor: University of California, Davis

Target Recruit Count: 72

Registration Number: NCT00261157

Locations: 🇺🇸
University of California, Davis, Sacramento, California, United States

Risedronate and Parathyroid Hormone to Reverse Osteoporosis Caused by Chronic Steroid Use

Phase 4

Completed

Conditions: Osteoporosis

Interventions: Drug: Risedronate
Drug: Parathyroid Hormone

First Posted Date: 2005-09-22

Last Posted Date: 2015-06-25

Lead Sponsor: University of California, Davis

Target Recruit Count: 60

Registration Number: NCT00221299

Locations: 🇺🇸
UC Davis General Medicine Research Clinic, Sacramento, California, United States

Monoclonal Antibody Therapy Plus Cyclosporine and Peripheral Stem Cell Transplantation in Treating Patients With Metastatic Breast Cancer

Phase 1

Conditions: Breast Cancer

First Posted Date: 2004-06-17

Last Posted Date: 2013-08-07

Lead Sponsor: University of California, Davis

Target Recruit Count: 18

Registration Number: NCT00003920

Locations: 🇺🇸
University of California Davis Medical Center, Sacramento, California, United States

Monoclonal Antibody Therapy, Chemotherapy, and Peripheral Stem Cell Transplantation in Treating Patients With Refractory Non-Hodgkin's Lymphoma

Phase 1

Conditions: Lymphoma

First Posted Date: 2003-06-02

Last Posted Date: 2013-08-07

Lead Sponsor: University of California, Davis

Registration Number: NCT00008021

Locations: 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States

Monoclonal Antibody Therapy, Paclitaxel, and Cyclosporine in Treating Patients With Recurrent or Refractory Non-Hodgkin's Lymphoma

Phase 1

Conditions: Lymphoma

First Posted Date: 2003-01-27

Last Posted Date: 2013-09-20

Lead Sponsor: University of California, Davis

Registration Number: NCT00009776

Locations: 🇺🇸
University of California Davis Cancer Center, Sacramento, California, United States

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy